ScholarOne Support telephone numbers and hours:
In U.S.: 434-817-2040 x 167
Outside U.S.: 001-434-817-2040
Available: Monday through Friday, 3:00AM to 5:30PM ET

Submission Instructions

Submit your manuscript through Manuscript Central or from www.cjasn.org, click on “Submit Your Manuscripts Online.” Type your existing login/password or click on “Create an Account.” Be careful not to create more than one account for yourself. Whether you are submitting a manuscript or reviewing a manuscript, you will use the same account information. You may make changes to the account at any time. Once you are logged in, you will see the different centers to which you have access. Click on “Author Center” and follow the instructions. The corresponding author must have e-mail access. Printed submissions are not accepted.

Manuscript Length
Regular Articles should not exceed 3000 words (excluding title page, figures, tables, and references). The word count must be noted on the title page of the manuscript.

Subjects appropriate for the Journal include but are not restricted to:

Requirements
Authors will be asked during the submission process to indicate that neither the manuscript nor any significant part of it is under consideration for publication elsewhere, or has appeared elsewhere in a manner that could be construed as a prior or duplicate publication of the same or very similar work. Abstracts are not considered prior publication, but should be cited in the Acknowledgements section. Should there be a possibility of doubt concerning such prior publications, the title page and abstract of such material should be included with the submitted paper.

With regard to authorship credit, ASN journals have adopted the criteria recommended by the International Committee of Medical Journal Editors (ICMJE) in the October 2005 update of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals:

“Authorship credit should be based on 1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.”

Also, as recommended by the ICMJE, “all contributors who do not meet the criteria for authorship should be listed in an acknowledgments section.” The ASN requires that all those who have participated in the writing of a paper be acknowledged by name and affiliation. Note the full text of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals.

In addition, with regard to contributors, ASN journals have adopted the following statement of editorial policy from the “Information for Authors” of the Annals of Internal Medicine: "Medical writers and industry employees can be legitimate contributors, and their roles, affiliations, and potential conflicts of interest should be described when submitting manuscripts. These writers should receive acknowledgment on the byline or in the acknowledgments section in accord with the degree to which they contributed to the work reported in the manuscript. The Editors consider failure to acknowledge these contributors ghostwriting, and ghostwriting is unacceptable."

Note that the ASN reserves the right to retract articles that do not meet the above criteria for authorship.

CJASN Authors are asked to divulge any relationships with pharmaceutical firms or other entities (such as employment contracts, consultancy, advisory boards, speaker bureaus, membership of Board or Directors, stock ownership) that could be perceived to represent a financial conflict of interest, or to declare that no financial conflict of interest exists.

Financial conflict of interest statements will be published at the end of the text of the article.

Declaration of Helsinki. For all clinical experimentation described in the manuscript, CJASN requires that authors state in the methods section their adherence to the Declaration of Helsinki. A statement that informed consent was obtained must also appear in the manuscript. For the full text of the Declaration of Helsinki, Click Here.

Copyright. Authors will be required to click on a check box during the submission process. By clicking on this check box, the corresponding author agrees that in consideration of the American Society of Nephrology’s (ASN) taking action in reviewing and editing this submission, the author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership to the ASN in the event that this work is published by the ASN in any format.

Permission to Reprint. If you are using material from any previously published articles, letters of permission from the publisher and/or author must be faxed to the Editorial Office (352-335-8100).

Randomized Controlled Trials. CJASN encourages authors submitting reports of randomized controlled trials to click here to review the CONSORT Statement. The CONSORT Statement includes recommendations, a checklist of items that should be included in a comprehensive report, and a participant-flow diagram. Reports of randomized controlled trials may be delayed in review if CONSORT guidelines are not followed.

Requirement for Registration of Clinical Trials
We require, as a condition of consideration for publication, registration in a public trials registry. Trials must register at or before the onset of patient enrollment. This policy applies to any clinical trial starting enrollment after January 1, 2006. For trials that began enrollment before this date, we require registration by April 1, 2006, before considering the trial for publication.

We define a clinical trial as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g. phase 1 trials) are exempt.

We do not advocate one particular registry, but registration must be with a registry that meets the following minimum criteria:

Registries that currently meet these criteria include:

The registry sponsored by the US National Library of Medicine (www.clinicaltrials.gov)
The International Standard Randomised Controlled Trial Number registry (www.controlled-trials.com)
The Cochrane Renal Group registry (www.cochrane-renal.org/trialsubmissionform.php)
The National (UK) Research Register (www.update-software.com/national/)
European Clinical Trials Database (http://eudract.emea.eu.int/)

Manuscript Checklist

Title Page

Abstract
1. The use of abbreviations is discouraged. Any abbreviations used must be defined in the abstract.
2. The abstract should be less than 250 words. It should consist of four paragraphs labeled:

Figures
1. The fee for publishing color figures is $500.00 per printed journal page. Authors are responsible for the cost of color pages. (Figures submitted in color will be printed in color.)

2. Figures must be cited in the text, in numerical order using Arabic numerals.

3. In the event that your manuscript is accepted, the Editorial Office will require you to upload your figures as EPS or TIFF files. They will also need to have passed Rapid Inspector. Therefore, while any type of file may be embedded within the manuscript file, it is recommended that graphics be prepared using a program which can save files in a format that can ultimately be saved and submitted as EPS or TIFF. Graphics should be saved in CMYK (cyan, magenta, yellow, black) rather than RGB (red, green, blue).

The resolution specification for TIFF and EPS files is 1200 dpi for monochrome, figures that are black and white only and line shots; 300 dpi for gray/CMYK or color photographs, and 600 dpi for combinations, such as photographs labeled with letters or other markings.

4. For additional information on submitting graphics or if you have questions regarding specifications for figure files, please visit Cadmus Knowledgeworks.

Reference Formats
References should be listed in order of their appearance in the article. There is a limit of 50 references per manuscript. List all authors for each article cited. Journal names should be abbreviated according to the BIOSIS list of serials.

Journal articles, books and abstracts:
1. Nangaku M, Pippin J, Couser WG: Complement membrance attack complex (C5b9) mediates interstitial disease in experimental nephritic syndrome. J Am Soc Nephrol 10: 2323-2332. 1999

2. May RC, Mitch WE: Pathophysiology of uremia. In: The Kidney, 5th ed., edited by Brenner BM, Philadelphia, WB Saunders, 1996, pp 2148-2169

3. Yoo KH, Norwood VF, Chevalier RL: Regulation of angiotensin II AT1 and AT2 receptors in neonatal unilateral urethral obstruction [Abstract]. J Am Soc Nephrol 6: 1035, 1995

Review Process
It is the policy of the Journal to expedite manuscript review. Authors will receive within 3 days an acknowledgment that their manuscript has been forwarded to an Associate Editor and appropriate reviewers. Manuscripts that are judged by the Editor-in-Chief and Deputy Editors to fall below the top 50% of manuscripts submitted to the Journal, or that fail to satisfy technical requirements, may be promptly returned to the authors without further review.

Submitting a Revised Manuscript
If you received a decision letter on your submission that indicated CJASN was interested in your manuscript if revisions are made, you can Create a Revision by clicking on your Corresponding Author Center, then click on Manuscripts with Decisions. You will then click Create a Revision on the specific manuscript. You may then follow the prompts to continue submission of the revised version.

Expedited Reports
Authors who believe their findings are of unusual interest or importance to nephrology are invited to submit a more succinct report to be considered for accelerated review and publication in the category Expedited Reports. The goal of Expedited Reports is the rapid publication of new findings of unique importance in clinical research or that lead to a new direction in research.

Papers submitted to Expedited Reports should not exceed 2,000 words, 3 figures and 50 references. Abstracts should not exceed 150 words, Materials and Methods should be condensed to the essentials required for review, and the Results and Discussion sections may be combined. Manuscripts should otherwise meet the criteria listed above for submission to CJASN. Letters of submission must contain a succinct description of why the paper should be considered for publication as an Expedited Reports. Submissions that do not meet these guidelines will be returned without further review.

Paper submitted to Expedited Reports will be peer reviewed through the usual process and considered for publication only if they are acceptable with no, or very minor, revisions thus removing the usual time required for revisions. They will be published in the next available issue following acceptance.

Manuscripts not selected for publication as an Expedited Report may be expanded and submitted as regular papers.

Accepted Manuscripts
After a manuscript has been accepted for publication, the authors will need to upload a final set of files as a revised manuscript. The text and tables will need to be sent as a Word Document (one file) and the figures as either a TIFF or EPS file. Please use Rapid Inspector. This pre-flight program will check graphics for compliance and printer requirements. If your graphic fails, Rapid Inspector will suggest methods to correct the problem. Manuscripts submitted to CJASN with failed graphics will be charged a $25.00 Failed Figure Fee and returned to the author for correction.

Embargo Policy
All information regarding the content and publication date of accepted manuscripts is strictly confidential. Information contained in or about accepted articles cannot appear in print, on radio or television, or in electronic form, or be released by the news media, until the article appears in the Publish-before-Print page on the CJASN website, or on the day the published version of CJASN is mailed, whichever comes first.

For information about publication dates for specific articles, please call Bob Henkel at 504-942-0902 or e-mail embargo@asn-online.org.

Proofs
Manuscripts will be copyedited, and electronic proofs will be made available for author approval. Authors will be notified by e-mail when their proofs are ready. Download, print, read, correct, and return the proofs within 48 hours. Be sure that all the editor’s or printer’s queries are answered. Only minor corrections are permitted.

Publication Fees
Page Charges: As of the January 2006 issue of CJASN, authors will be charged $60.00 per manuscript page.

Color Charges: As of the January 2006 issue of CJASN, authors will be charged $500.00 per color (Figures submitted in color will be printed in color.) page.

Failed Figure Charges: As of the January 2006 issue of CJASN, authors will be charged $50.00 per failed figure.

Invited reviews and editorials will be exempt from these charges.

Authors from institutions in countries with a gross national product (GNP)per capita below $3,000 will not be charged for pages or color figures. To view a list of eligible countries please visit http://www.who.int/hinari/eligibility/en/index.html

Reprints
Authors of articles published in the CJASN will receive reprint order forms with the page proofs. Alternatively, reprints may be ordered via Cadmus Professional Communications. Contact Anna Sobotor, Reprint Account Manager, or call 800-407-9190.

Pricing includes the purchase of reprints by the author(s) for personal use only. Non-authors can purchase reprints via Cadmus Professional Communications. Contact Heather Edwards or call 410-691-6214.

Disclaimer
The statements and opinions contained in the articles of the Clinical Journal of the American Society of Nephrology are solely those of the individual authors and contributors and not of the American Society of Nephrology. The appearance of advertisements in the Journal is not a warranty, endorsement or approval of the products or services advertised or of their safety. The American Society of Nephrology disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.